<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02659332</url>
  </required_header>
  <id_info>
    <org_study_id>URU05</org_study_id>
    <nct_id>NCT02659332</nct_id>
  </id_info>
  <brief_title>Laser Treatment of Bladder Tumors in the Outpatient Department</brief_title>
  <official_title>Diode Laser Treatment of Pta Low Grade Bladder Tumors in the Outpatient Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gregers G Hermann</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Primary Objective: To show that small pTa bladder tumors can be removed with diode laser
           in an outpatient department.

        -  Secondary Objective: To evaluate the patients' symptoms during and after the laser
           TURBT.

        -  Tertiary Objective: To evaluate the rate of remnant tumor tissue one month after the
           laser TURBT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients will have a PDD guided flexible cystoscopy performed and the bladder tumor will
      be removed by a diode laser (400μm fiber, 6-12W, laser pulse 1ms and intervals of1ms).The
      treatment will take place in the OPD in awaken patients. One hour prior to the treatment the
      patient will have Hexvix® (photodynamic substance) and Lidocaine 20 ml (pain treatment)
      installed in the bladder. Simultaneous pain treatment will be oral Paracetamol 1 g and
      Ibuprofen 600 mg. Biopsy from the tumor will be taken to confirm the histological diagnosis.

      Immediately after the procedure the pain assessed by the VAS score will be recorded and the
      patients are given a QOL questionnaire (EORTC QLQ-BLS24) and a stamped envelope and are asked
      to return it one week later. The patients will be telephoned after 5 days to remind on the
      questionnaire and to ash, whether they has had a urinary infection after the procedure.

      One month after the laser TURBT a flexible PPD and SPIES guided cystoscopy is performed in
      the OPD to evaluate the laser efficacy. To confirm that all tumour tissue has been removed a
      biopsy will be taken from the previous tumor place. The biopsy will be send to the
      pathologist according to the normal procedure for biopsies. Visual presentation of the laser
      treated area will be visualized using PDD and SPIES.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Removal by One Laser Treatment (Proportions of patients where the bladder tumors are completely removed by one laser)</measure>
    <time_frame>one month</time_frame>
    <description>Proportions of patients where the bladder tumors are completely removed by one laser treatment.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Bladder Tumors</condition>
  <arm_group>
    <arm_group_label>TURBT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diode laser (400μm fiber, 6-12W, laser pulse 1ms and intervals of1ms)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TURBT</intervention_name>
    <description>Diode laser (400μm fiber, 6-12W, laser pulse 1ms and intervals of 1 ms)</description>
    <arm_group_label>TURBT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recurrence of pTa low grade urothelial bladder tumor

          -  Tumor &lt; 1.5 cm

          -  &lt; 6 tumors

        Exclusion Criteria:

          -  Patients with porphyria

          -  Known hypersensitivity to Hexvix® or porfhyrins

          -  Use of any anticoagulantia

          -  Macroscopic hematuria

          -  Pregnant or breast feeding women

          -  Expected poor compliance

          -  Patients &lt; 18 years

          -  Patients who do not read or understand Danish
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregers G Hermann, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg and Frederiksberg Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Urology, Bispebjerg and Frederiksberg Hospital</name>
      <address>
        <city>Frederiksberg</city>
        <state>Copenhagen</state>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013 Apr;49(6):1374-403. doi: 10.1016/j.ejca.2012.12.027. Epub 2013 Feb 26.</citation>
    <PMID>23485231</PMID>
  </reference>
  <reference>
    <citation>Sangar VK, Ragavan N, Matanhelia SS, Watson MW, Blades RA. The economic consequences of prostate and bladder cancer in the UK. BJU Int. 2005 Jan;95(1):59-63.</citation>
    <PMID>15638895</PMID>
  </reference>
  <reference>
    <citation>van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA, Zlotta AR. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009 Sep;56(3):430-42. doi: 10.1016/j.eururo.2009.06.028. Epub 2009 Jun 26. Review.</citation>
    <PMID>19576682</PMID>
  </reference>
  <reference>
    <citation>James AC, Gore JL. The costs of non-muscle invasive bladder cancer. Urol Clin North Am. 2013 May;40(2):261-9. doi: 10.1016/j.ucl.2013.01.004. Epub 2013 Feb 13.</citation>
    <PMID>23540783</PMID>
  </reference>
  <reference>
    <citation>Hofstetter A, Frank F, Keiditsch E, Böwering R. Endoscopic Neodymium-YAG laser application for destroying bladder tumors. Eur Urol. 1981;7(5):278-82.</citation>
    <PMID>6894732</PMID>
  </reference>
  <reference>
    <citation>Davenport K, Keeley FX Jr, Timoney AG. Audit of safety, efficacy, and cost-effectiveness of local anaesthetic cystodiathermy. Ann R Coll Surg Engl. 2010 Nov;92(8):706-9. doi: 10.1308/003588410X12699663904835. Epub 2010 Jul 2.</citation>
    <PMID>20615299</PMID>
  </reference>
  <reference>
    <citation>Syed HA, Talbot N, Abbas A, MacDonald D, Jones R, Marr TJ, Rukin NJ. Flexible cystoscopy and Holmium:Yttrium aluminum garnet laser ablation for recurrent nonmuscle invasive bladder carcinoma under local anesthesia. J Endourol. 2013 Jul;27(7):886-91. doi: 10.1089/end.2012.0696. Epub 2013 Jun 22.</citation>
    <PMID>23537221</PMID>
  </reference>
  <reference>
    <citation>Wong KA, Zisengwe G, Athanasiou T, O'Brien T, Thomas K. Outpatient laser ablation of non-muscle-invasive bladder cancer: is it safe, tolerable and cost-effective? BJU Int. 2013 Sep;112(5):561-7. doi: 10.1111/bju.12216. Epub 2013 Jul 2.</citation>
    <PMID>23819486</PMID>
  </reference>
  <reference>
    <citation>Hermann GG, Mogensen K, Toft BG, Glenthøj A, Pedersen HM. Outpatient diagnostic of bladder tumours in flexible cystoscopes: evaluation of fluorescence-guided flexible cystoscopy and bladder biopsies. Scand J Urol Nephrol. 2012 Feb;46(1):31-6. doi: 10.3109/00365599.2011.637954. Epub 2011 Dec 12.</citation>
    <PMID>22150596</PMID>
  </reference>
  <reference>
    <citation>Turrentine FE, Wang H, Simpson VB, Jones RS. Surgical risk factors, morbidity, and mortality in elderly patients. J Am Coll Surg. 2006 Dec;203(6):865-77.</citation>
    <PMID>17116555</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2016</study_first_submitted>
  <study_first_submitted_qc>January 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2016</study_first_posted>
  <last_update_submitted>January 20, 2016</last_update_submitted>
  <last_update_submitted_qc>January 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Bispebjerg Hospital</investigator_affiliation>
    <investigator_full_name>Gregers G Hermann</investigator_full_name>
    <investigator_title>MD, DM Sc.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

